Apelin analogues
AssigneeUniveristy of Ulster
InventorsFinbarr Paul Mary O'Harte, Peter Raymond Flatt
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition with a peptide analog of apelin, and a method of treatment for various conditions are described. An exemplary embodiment is a peptide analog comprising at least residues 2-13 of SEQ ID NO: 1 and further comprising at least a substitution or modification at residue 13 of SEQ ID NO: 1. A pharmaceutical composition comprising the peptide analog of the present invention and method of treatment for diabetes, stimulating insulin release, and moderating blood glucose excursions by administering the peptide analog of the present invention to a patient in need thereof are described.
Claims14
A peptide analogue comprising at least residues 2-13 of SEQ ID NO:
- 1 and further comprising at least one from the group consisting of a substitution and a modification at residue 13 or SEQ ID NO:
- 1;
- those amino acids present at positions 2-7 and 9-12 of the peptide analogue are unsubstituted with respect to the corresponding residues of SEQ ID NO:
- 1;
- an N-terminal addition with at least one from the group consisting of pGlu (5-oxoproline), an acetyl moiety, an acyl moiety, and an acylated moiety;
- and
- a modification at residue 8 of SEQ ID NO:
- 1.
A peptide analogue consisting of at least residues 2-13 of SEQ ID NO:
- 1, wherein residue 13 is the C-terminal residue and the terminal carboxyl group of residue 13 is replaced by an amide group;
- and
- comprising an N-terminal addition of pGlu (5-oxoproline) or an acetyl, acyl or acylated moiety;
- and
- comprising a modification at residue 8 of SEQ ID NO:
- 1.
A peptide comprising pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys(gluPAL)-Gly-Pro-Met-Pro-Phe-amide.
Dependencies are inferred from the claim text.